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Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.
Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive
breast cancer to 5 years adjuvant endocrine therapy with tamoxifenþOFS, exemestaneþOFS or tamoxifen alone. The Co-SOFT
substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the
primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data
were compared for the pooled tamoxifenþOFS and exemestaneþOFS groups vs the tamoxifen alone group using the Wilcoxon
rank-sum test.
Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFSþ either tamoxifen (28) or
exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite
cognitive function scores between the OFSþ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d.,
 0.21±0.92 vs  0.04±0.49, respectively, P¼ 0.71, effect size¼  0.20), regardless of prior chemotherapy status, and adjusting
for baseline characteristics.
Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral
endocrine therapy substantially affects global cognitive function.
Adjuvant endocrine therapy with the selective oestrogen receptor
modulator tamoxifen reduces mortality and has long been a
standard of care for premenopausal women with potentially
curable hormone receptor-positive breast cancer (Early Breast
Cancer Trialists’ Collaborative Group, 2005; Burstein et al, 2014).
Two recent randomised trials, TEXT and Suppression of Ovarian
Function Trial (SOFT), have shown that ovarian function
suppression (OFS), in combination with either the aromatase
inhibitor exemestane or tamoxifen, provides additional benefit over
tamoxifen alone (Pagani et al, 2014; Francis et al, 2015). On the
basis of these results, OFS will be increasingly used as part of the
adjuvant treatment of premenopausal women with hormone
receptor-positive breast cancer (Coates et al, 2015).
In choosing the most appropriate adjuvant endocrine therapy
for an individual woman, side-effect profile is a major considera-
tion (Hershman, 2015). It has been shown that women who
experienced more side-effects required a greater survival benefit to
accept adjuvant endocrine therapy (Thewes et al, 2005). Cognitive
dysfunction is a much feared potential side-effect of breast cancer
treatment (Haiken, 2015). Studies suggest that all components of
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cancer treatment may impair cognition (Janelsins et al, 2014) and
that impairment may also be present in some women prior to
cancer treatment (Scherling et al, 2012). It is clear that oestrogen
has an important role in cognitive functioning (Sherwin, 2012) but
few studies have examined the effect of adjuvant endocrine therapy
for breast cancer on cognitive function (Phillips et al, 2010,
2011a, b; Schilder et al, 2010; Ganz et al, 2014) and none has
assessed the impact of OFS. OFS results in very-low circulating
oestrogen levels and some (Varney et al, 1993; Grigorova et al,
2006; Craig et al, 2007), but not all (Owens et al, 2002; Schmidt
et al, 2013) data from non-oncological settings suggest that OFS
with gonadotropin-releasing hormone agonists (GnRH) agents
impair cognition and that this impairment can be reversed with
add-back oestrogen (Sherwin and Tulandi, 1996). It has also been
reported that surgical menopause adversely affects cognition
(Rocca et al, 2007; Ryan et al, 2014).
We conducted a cognitive function substudy of the SOFT. The
primary objective of this Co-SOFT substudy was to compare
changes in cognitive function, measured objectively over 1 year in
premenopausal patients with breast cancer who received adjuvant
endocrine therapy with OFS (either tamoxifenþOFS or exemes-
tane þOFS) against those who received tamoxifen alone. It was
hypothesised that, because of greater oestrogen deprivation,
women who received OFS would have greater deterioration in
cognitive function than those who received tamoxifen alone.
MATERIALS AND METHODS
The SOFT trial was an international, three-arm, non-blinded,
randomised trial in premenopausal women with hormone
receptor-positive breast cancer (Francis et al, 2015). It evaluated
the efficacy of 5 years of adjuvant hormonal therapy using OFS
plus tamoxifen or OFS plus exemestane or tamoxifen alone. Prior
chemotherapy was allowed, provided women had premenopausal
oestradiol levels after completing all chemotherapy and before
enroling in the SOFT study. Women were stratified at randomisa-
tion according to whether they received adjuvant chemotherapy
prior to randomisation, axillary lymph node status and intended
initial method of OFS (women could choose between the GnRH
agonist triptorelin, surgical oophorectomy or ovarian irradiation).
Patients were enrolled within 12 weeks of their definitive breast
cancer surgery or, for those who received chemotherapy, within 8
months of completing chemotherapy. Between November 2003
and January 2011, 3066 women were randomised on the
SOFT trial.
Patients. To be eligible for the Co-SOFT substudy, women must
have been registered for the SOFT study but not yet received any
adjuvant endocrine therapy, and they must have been able to speak
and write the local language fluently and have provided written
informed consent. To minimise the potential for sampling bias,
participating centres were to enrol all eligible patients. The
substudy protocol was approved by the local and International
Breast Cancer Study Group (IBCSG) ethics committees and the
required health authorities of each participating centre.
Measures. At baseline before the start of protocol therapy (T0)
and at B1 year after randomisation to the SOFT study (T1)
objective cognitive function was tested and patients provided self-
reported data on cognitive function, psychological distress, fatigue,
insomnia and quality of life.
Objective cognitive function. Objective cognitive function was
measured with the CogState computerised test battery (CogState
Ltd; http://www.cogstate.com); a brief test designed specifically for
repeated application and free from practice effects (Falleti et al,
2003; Silbert et al, 2004; Vardy et al, 2006). Testing consisted of five
non-verbal tasks, measuring the speed of psychomotor function,
visual attention, attention and working memory, and visual
learning and memory. In addition, two verbal learning and
memory tasks required subjects to learn a 12-word shopping list,
and then to recall this list after 20minutes (Table 1). Details of the
test battery have been described elsewhere (Phillips et al, 2010). For
the seven tasks, a composite score, representing the age-adjusted
average standardised score of each task for each individual, was
calculated (Phillips et al, 2010). This provides a measure of global
cognitive function that has been validated psychometrically
(Maruff et al, 2009) and empirically in studies of pharmacological
agents (Snyder et al, 2005; Maruff et al, 2006), head injury
(Collie et al, 2001), fatigue (Falleti et al, 2003) and surgery (Silbert
et al, 2004).
Patient reported outcomes. After cognitive testing, women
completed several questionnaires. Self-reported cognitive function
was assessed by the Cognitive Failures Questionnaire (CFQ)
(Broadbent et al, 1982), a 25-item questionnaire that assesses the
frequency of failures in memory, perception and motor function
over the past 6 months. To measure psychological distress, a
12-item version of the General Health Questionnaire (Goldberg
and Williams, 2000) was used. In addition, the Brief Fatigue
Inventory (Mendoza et al, 1999), a nine-item instrument to assess
severity of fatigue and its inference with daily living in a 24 h
period, was administered. Global quality of life domains (physical
well-being, mood, coping effort, subjective health estimation) as
well as symptom-specific quality of life domains (nausea and
vomiting, appetite, tiredness, hot flushes, restriction in arm
movements and insomnia) were measured by linear analogue
self-assessment indicators (Bernhard et al, 2015). Validated
language versions were used where available, otherwise a standard
translation procedure was performed (forward-backward).
Statistical considerations. The protocol-specified primary com-
parison was the change in the composite score of the CogState
tasks over 1 year for women randomised to tamoxifen þOFS vs
tamoxifen alone. Due to low accrual to the substudy, this was
modified, prior to any analysis, to compare the pooled tamoxifen
Table 1. Tasks and cognitive domains assessed by the CogState battery
Task Cognitive Domain Assessed Type of test Unit of measurement
Detection Speed of psychomotor function Performance speed Log10 milliseconds
Identification Visual attention Performance speed Log10 milliseconds
Monitoring Visual attention Performance speed Log10 milliseconds
Memory Attention and working memory Performance accuracy Arcsine proportion correct
Learning Visual learning and memory Performance accuracy Arcsine proportion correct
ISLT Verbal learning and memory Performance accuracy Total number correct
Delayed ISLT Verbal learning and memory Performance accuracy Total number correct
Abbreviation: ISLT¼ International Shopping List Test.
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þOFS and exemestaneþOFS groups with the tamoxifen alone
group. The observed sample size provided 80% power to detect an
effect size of 0.76 with two-sided a¼ 0.05. Cognitive test scores were
transformed (Phillips et al, 2010), standardised according to age-
specific norms, and the resulting Z-scores averaged to calculate the
composite score (Maruff et al, 2009). Individual Z-scores more than
1.96 s.d. below the norm were defined as ‘impaired.’ The change in
composite scores between T0 and T1 were calculated; a negative
change in composite score indicated deterioration in cognitive
function. Changes in composite score and individual tasks were
compared between treatment groups using Wilcoxon rank-sum tests.
Effect sizes for the comparison of treatments were calculated as mean
change in OFS groups minus mean change in tamoxifen alone group
divided by the pooled s.d. of the change (Cohen, 1988) for the
composite score and each task. According to convention, effect sizes
of þ 0.2 was considered small, þ 0.5 moderate and þ 0.8 large
(Cohen, 1988). Sensitivity analyses compared treatment groups using
regression modelling, adjusting for patient, disease and treatment
characteristics at baseline: language and treatment assignment, age,
family history of breast cancer, body mass index, menstruation status,
history and/or treatment of anxiety/depression, nodal status and
prior chemotherapy and use of HER2-targeted treatment. Character-
istics were compared between treatment groups using Fisher’s exact
tests. Spearman’s correlation coefficients were calculated between
composite score and patient-reported outcome measures.
RESULTS
Co-SOFT commenced recruitment in October 2007 and after 26
Co-SOFT centres were activated, 86 of 102 (84%) eligible women
enrolled in SOFT and with no prior endocrine therapy were
recruited. Planned accrual was 321 patients but Co-SOFT was
closed in January 2011 because the SOFT trial had completed
accrual. Patient, demographic, medical, disease and treatment
characteristics were similar between those eligible women at
participating centres who did and those eligible women who did
not participate in Co-SOFT (data not shown). Of 86 Co-SOFT
participants, 74 underwent both T0 and T1 cognitive function
testing and were included in the primary analysis (8 withdrew
consent or declined assessment, 4 missed testing for administrative
reasons). Of the 74 evaluable patients, 54 were randomised to
OFSþ oral endocrine therapy (OFSþ tamoxifen n¼ 28 or OFSþ
exemestane n¼ 26) and 20 were randomised to tamoxifen alone
(Figure 1).
As shown in Table 2, baseline characteristics were well-balanced
between the two groups. During the first year 49 women had
GnRH agonist alone for OFS, 4 had GnRH followed by
oophorectomy and 1 had oophorectomy.
Figure 2 shows the change in objective cognitive function
between T0 and T1 by study treatment assignment. There was no
significant difference in the changes in the CogState composite
scores from T0 to T1 for patients randomised to OFSþ oral
endocrine therapy compared with tamoxifen alone (mean±s.d.,
 0.21±0.92 vs  0.04±0.49, respectively, P¼ 0.71, effect size¼
 0.20). This was true regardless of whether women had received
prior chemotherapy, and adjusting for baseline characteristics.
Women who received OFS showed greater deterioration in the
International Shopping List Task (ISLT) than those who received
tamoxifen alone (mean±s.d.  0.20±0.68 vs 0.29±0.73 respec-
tively, P¼ 0.02, effect size¼  0.68). For the other six tasks there
were small effect sizes and no statistically significant difference
between the two treatment groups.
Table 3 shows the number of women that met the definition for
impairment on each cognitive task at each timepoint. The task for
which the largest proportion of women changed from normal to
Tamoxifen (N = 25)
Excluded (N = 5)
• Withdrew consent/
  declined assessment (N = 3)
• Administrative/logistical (N = 2)
Tamoxifen+OFS (N = 32) Exemestane+OFS (N = 29)
Enrolled in Co-SOFT substudy
(N = 86 of 102 having no prior ET)
OFS group (N = 54)
Excluded (N = 4)
• Withdrew consent/
  declined assessment (N = 2)
• Administrative/logistical (N = 2)
Excluded (N = 3)
• Withdrew consent/
declined assessment (N = 3)
Tamoxifen group (N = 20)
Cognitive assessment at baseline (T0) and at year 1 (T1)
All treatments 5 years duration from randomisation
Enrolled in SOFT, Dec 2003 – Jan 2011
All centres (N = 3066; 2289 (75%) no prior ET)
26 Co-SOFT centres (N = 451; 337 (75%) no prior ET)
Enrolled during Co-SOFT activity, Oct 2007 – Jan 2011
All centres: (N = 1702; 1210 (71%) no prior ET)
26 Co-SOFT centres: (N = 261; 179 (70%) no prior ET)
Enrolled after centre began participation in Co-SOFT
(N = 138; 102 (74%) no prior ET)
Figure 1. CONSORT Flow Diagram showing the design and enrolment to the Co-SOFT substudy. Eligible patients were enrolled in the substudy
at the time of randomisation to SOFT. ET¼endocrine therapy.
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impaired status between T0 and T1 was the learning task; for
which 22% of those on OFS and 15% of those on tamoxifen went
from normal to impaired and conversely 7% of those on OFS and
20% of those on tamoxifen went from impaired to normal. It has to
be noted that the numbers in the various subgroups are too small
for a conclusive interpretation.
Table 4 shows the patient reported outcome data. The change in
self-reported cognitive function between T0 and T1 indicated
greater decline in patients receiving OFS vs those receiving
tamoxifen alone (mean±s.d., 7.8±13.1 vs 1.1±9.7, effect
size¼ 0.53). Note that higher CFQ scores indicate worse self-
reported cognitive function, thus a positive change score indicates
deterioration. No correlation was observed between objective
cognitive function (CogState composite cognitive function
score) and self-reported cognitive function (r¼  0.12), fatigue
(r¼  0.05), psychologic distress (r¼ 0.06) or quality of life
indicators (range, r¼  0.09 to 0.16) including insomnia
(r¼ 0.11), at year 1. However, self-reported cognitive function
was moderately and positively correlated with fatigue (r¼ 0.55)
and psychologic distress (r¼ 0.53) and was low to moderately
correlated with quality of life indicators (range, r¼  0.13 to
 0.45), including insomnia (r¼  0.31), at year 1.
Table 2. Patient, disease and treatment characteristics at T0
OFS Tam All
Characteristic N % N % N % P-valuea
N patients 54 20 74 —
Age at randomisation 0.56
Mean (range) 44 (28–58) 46 (38–53) 45 (28–58)
o35 5 9.3 — — 5 6.8
35–39 4 7.4 2 10.0 6 8.1
40–44 15 27.8 5 25.0 20 27.0
45–49 21 38.9 7 35.0 28 37.8
50þ 9 16.7 6 30.0 15 20.3
Education 1.00
Primary/secondary education 9 16.7 3 15.0 12 16.2
Additional education 31 57.4 12 60.0 43 58.1
Academic education 14 25.9 5 25.0 19 25.7
Body mass index 0.94
Normal (o25) 30 55.6 11 55.0 41 55.4
Overweight (25–o30) 13 24.1 4 20.0 17 23.0
Obese (X30) 9 16.7 4 20.0 13 17.6
Unknown 2 3.7 1 5.0 3 4.1
Menstruation 0.79
Normal 36 66.7 13 65.0 49 66.2
Irregular (but cycles continuing) 7 13 4 20.0 11 14.9
Persistent amenorrhoea 11 20.4 3 15.0 14 18.9
Performance status 1.00
Fully active (K90–100) 48 88.9 18 90.0 66 89.2
Restricted (K70–80) 6 11.1 2 10.0 8 10.8
History and/or treatment of depression/anxiety 0.41
No 33 61.1 15 75.0 48 64.9
Yes 21 38.9 5 25.0 26 35.1
Nodal status 0.75
Negative 42 77.8 17 85.0 59 79.7
Positive 12 22.2 3 15.0 15 20.3
Local-regional treatment 0.92
Mastectomy, no radiation 13 24.1 4 20.0 17 23.0
Mastectomy with radiation 6 11.1 2 10.0 8 10.8
Breast-conserving with radiation 35 64.8 14 70.0 49 66.2
Weeks from randomisation to completion of radiation if received, median (interquartile range) 7.4 (1.9–9.7) 7 (2.1–13.4) 7.4 (1.9–10.0)
Prior chemotherapy 0.78
No 38 70.4 15 75.0 53 71.6
Yes 16 29.6 5 25.0 21 28.4
Months from last dose of chemotherapy, median (interquartile range) 2.1 (1.7–2.8) 2.1 (1.9–2.4) 2.1 (1.8–2.7)
HER2 status and therapy 1.00
Not HER2þ 51 94.4 19 95.0 70 94.6
HER2þ /HER2-directed therapy 3 5.6 1 5.0 4 5.4
Type of OFS during year 1 NA
GnRH agonist only 49 90.7 NA —
GnRH agonist followed by oophorectomy 4 7.4 NA —
Oophorectomy only 1 1.9 NA —
Abbreviations: NA¼not applicable; OFS¼ovarian function suppression.
aPatient, disease and prior treatment characteristics were compared between groups using Fisher’s exact tests for categorical variables.
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Composite score Detection Identification Monitoring Memory Learning ISLT Delayed ISLT
CogState battery task
OFS (n = 54) Tamoxifen (n = 20)
Effect Size –0.20 –0.24 –0.08 0 –0.02 0.06 –0.68 –0.22
P-value 0.71 0.64 0.99 0.35 0.86 0.59 0.02 0.49
Figure 2. Mean change in CogState test performance between T0 (baseline) and T1 (one year) according to treatment assignment for the
composite score and the seven cognitive tasks assessed by the CogState battery. A negative change in individual task or composite score
indicates deterioration in cognitive function. ISLT, international shopping list test.
Table 3. Normal/Impaired CogState task scores according to treatment assignment
Normal T0 & Normal T1 Impaired T0 & Impaired T1 Normal T0-Impaired T1 Impaired T0-Normal T1
N (%) N (%) N (%) N (%)
Task Tam OFS Tam OFS Tam OFS Tam OFS
Detection 16(80) 50(93) 1(5) 1(2) 0(0) 1(2) 3(15) 2(4)
Identification 18(90) 53(98) 0(0) 0(0) 2(10) 0(0) 0 (0) 1(2)
Monitoring 18(90) 45(83) 0(0) 3(6) 2(10) 2(4) 0(0) 4(7)
Memory 16(80) 48(89) 1(5) 0(0) 1(5) 3(6) 2(10) 3(6)
Learning 7(35) 28(52) 6(30) 10(19) 3(15) 12(22) 4(20) 4(7)
ISLT 19(95) 52(96) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
Delayed ISLT 20(100) 53(98) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
Abbreviations: ISLT¼ International Shopping List Test; OFS¼ovarian function suppression. Impairment was defined as a score more than 1.96 s.d. below the age-adjusted norm. Note % may
not add to 100 due to missing data (for ISLT and delayed ISLT).
Table 4. Patient reported outcomes data
T0 T1 Change from T0 to T1
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Patient Reported Outcome Tam OFS Tam OFS Tam OFS
Cognitive Failures Questionnairea 32.1 (12.0) 32.7 (14.5) 32.3 (12.4) 40.2 (18.0) 1.1 (9.7) 7.8 (13.1)
General Health Questionnaire 12 25.7 (5.1) 24.5 (4.8) 23.7 (4.9) 25.3 (6.6)  2.1 (5.2) 0.9 (5.9)
Brief Fatigue Inventory 3.2 (2.3) 2.9 (1.8) 3.0 (2.2) 3.7 (2.2)  0.1 (1.9) 0.7 (2.3)
Physical Well-Being 71 (25) 74 (25) 71 (25) 69 (23) 0 (37)  5 (30)
Mood 70 (23) 69 (26) 72 (25) 68 (24) 2 (35) 0 (29)
Tiredness 62 (26) 59 (31) 57 (28) 50 (29) 5 (37)  9 (33)
Appetite 75 (25) 81 (21) 85 (17) 80 (21) 10 (32)  2 (24)
Hot Flushes 83 (23) 84 (27) 62 (29) 41 (30) 21 (32)  42 (37)
Nausea and Vomiting 89 (21) 94 (14) 82 (25) 91 (17) 6 (37)  3 (19)
Coping Efforts 66 (29) 69 (28) 80 (23) 72 (26) 14 (31) 3 (29)
Arm Restricted 79 (28) 76 (29) 79 (28) 84 (22) 0 (25) 9 (26)
Subjective Health Estimation 71 (26) 70 (24) 80 (22) 70 (23) 8 (28) 0 (26)
Insomnia 67 (25) 70 (29) 65 (27) 56 (29) 1 (32)  13 (33)
Abbreviations: CFQ¼Cognitive Failures Questionnaire; OFS¼ovarian function suppression.
aNote-higher CFQ scores indicate worse self-reported cognitive function.
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DISCUSSION
The study results do not provide evidence that the addition of OFS
to oral adjuvant endocrine therapy for breast cancer affects
objective global cognitive function in a clinically meaningful way
over 1 year of endocrine treatment. However, the study did not
have adequate power to detect a small to moderate effect on
cognitive function. The only cognitive task for which performance
of women randomised to OFS deteriorated significantly more
than those randomised to tamoxifen alone was a test of verbal
learning and memory, the ISLT. Some studies have suggested that
verbal memory is particularly affected by OFS in non-oncological
settings (Craig et al, 2007); however, we did not find a difference
between the OFS and tamoxifen alone groups in terms of
amount of deterioration in another measure of verbal memory,
the delayed ISLT.
Previous studies in this field have focussed on tamoxifen and the
aromatase inhibitors, nevertheless the impact of these drugs on
cognitive function remains poorly understood (Buwalda and
Schagen, 2013). Most studies have been observational, with
important differences between treatment groups that limits the
interpretation of associations of particular endocrine treatments
with cognitive changes. One randomised study tested postmeno-
pausal patients before and 1 year after commencing endocrine
therapy and compared those randomised to tamoxifen treatment
with those randomised to the aromatase inhibitor exemestane
and also included a healthy control group (Schilder et al, 2010).
It revealed that women randomised to tamoxifen had worse
information processing speed after one year compared with those
randomised to exemestane. In the non-randomised comparison
with healthy controls exemestane did not seem to impact cognitive
function adversely. The lack of impact of aromatase inhibitors on
cognitive function is also supported by the results of the cognitive
function substudy of the randomised IBIS II chemoprevention
trial, which showed that postmenopausal women randomised to
the aromatase inhibitor anastrozole had similar cognitive function
after 2 years compared with those randomised to placebo (Jenkins
et al, 2008). Similarly in the randomised BIG 1–98 study,
postmenopausal women taking the aromatase inhibitor letrozole
during year 5 of adjuvant endocrine therapy had better global
cognitive function than those taking tamoxifen (Phillips et al,
2010) and cognitive function in both groups improved after
cessation of adjuvant endocrine therapy (Phillips et al, 2011a).
Although no previous study has examined the impact of
adjuvant OFS on cognitive function, several studies have attempted
to assess the impact of chemotherapy-induced premature ovarian
insufficiency with mixed results (Jenkins et al, 2006; Schagen et al,
2006; Hermelink et al, 2008; Vearncombe et al, 2011). Recently a
longitudinal neuroimaging study showed that women who had
chemotherapy-induced amenorrhoea showed increases in brain
activation from pre to post-chemotherapy, suggesting compensa-
tory neural activation; no increases were seen in women who did
not have chemotherapy-induced amenorrhoea or healthy controls
(Conroy et al, 2013).
In our study, there was greater deterioration in self-reported
cognitive function in the OFS group compared with the group that
received tamoxifen alone. This was an unplanned exploratory
analysis and needs further prospective evaluation; however, many
previous studies have found that subjective cognitive complaints
are often worse than would be expected from objective cognitive
function testing (Hutchinson et al, 2012). There are several
possible explanations for this discrepancy, but studies that have
incorporated functional brain imaging suggest that patients that
complain of cognitive dysfunction may reach normal performance
on objective cognitive function tests by activating other brain areas
not usually directly related to the cognitive task, and this may be
perceived as greater effort (Hutchinson et al, 2012). Our finding
that self-reported cognitive function was moderately correlated
with fatigue and psychologic distress is consistent with most
previous studies (Hutchinson et al, 2012).
The strengths of our study include the longitudinal design with
a well-defined and homogenous sample of SOFT patients who had
not commenced endocrine therapy, defined type and duration of
endocrine therapy that was randomly assigned and the ability to
control for potential confounding factors. Small sample size is the
main limitation of our study, which resulted in limited power to
detect a small, but potentially meaningful, effect, as might be
anticipated when comparing two groups of patients receiving
endocrine therapies. There is potential for sampling bias, as
substudy centres enrolled only 84% of eligible patients, and the
possibility that the treatment assignment was part of the decision
cannot be excluded. In the future, consideration perhaps should be
given to incorporating measures of cognitive function in the main
study protocol, as is often done for quality of life measures, in
order to avoid having uninformative data on the effects of
new treatments on cognition. Other limitations include the absence
of a control group not treated with any endocrine therapy and the
lack of hormone testing to confirm the functional gonadal status of
the women, particularly those in the tamoxifen arm, some of
whom may have had chemotherapy-induced hypogonadism at T1.
Also, our cognitive function test battery did not include a measure
of verbal fluency and cognitive function was assessed only over the
first year of adjuvant endocrine therapy, which perhaps allowed
time for development of some compensation for any cognitive
dysfunction related to the endocrine therapy.
Given the importance of this clinical question for women, the
strong biological basis for a potential effect of OFS on cognitive
function, and the limitations of our study, we believe further study
of the impact of adjuvant OFS on cognitive function in breast
cancer patients is warranted.
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